SUPPLEMENTAL MABA AMENDMENT TO STRATEGIC ALLIANCE AGREEMENTStrategic Alliance Agreement • May 24th, 2012 • Theravance Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMay 24th, 2012 Company Industry JurisdictionThis Amendment to the Strategic Alliance Agreement (this “Amendment”) is entered into effective as of October 3, 2011 (the “Effective Date of this Amendment”), between Theravance, Inc., a Delaware corporation (“Theravance”) and Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales (“GSK”) and amends and supplements the Strategic Alliance Agreement entered into as of March 30, 2004, as amended and supplemented on September 13, 2004, February 11, 2005, February 8, 2006, February 27, 2006, February 27, 2009, June 22, 2009 and July 16, 2010 (the “Agreement”). All capitalized terms not defined in this Amendment shall have the meaning ascribed to them in the Agreement.
SUPPLEMENTAL MABA AMENDMENT TO STRATEGIC ALLIANCE AGREEMENTStrategic Alliance Agreement • February 27th, 2012 • Theravance Inc • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 27th, 2012 Company Industry JurisdictionThis Amendment to the Strategic Alliance Agreement (this “Amendment”) is entered into effective as of October 3, 2011 (the “Effective Date of this Amendment”), between Theravance, Inc., a Delaware corporation (“Theravance”) and Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales (“GSK”) and amends and supplements the Strategic Alliance Agreement entered into as of March 30, 2004, as amended and supplemented on September 13, 2004, February 11, 2005, February 8, 2006, February 27, 2006, February 27, 2009, June 22, 2009 and July 16, 2010 (the “Agreement”). All capitalized terms not defined in this Amendment shall have the meaning ascribed to them in the Agreement.